The Comparison of Clinical Efficacy, Fusion Gene,Serum Markers and Prognosis of Crizotinib and Non-crizotinib treatment for EML4-ALK Positive  Patients with Non Small Cell Lung Cancer

doi:10.11748/bjmy.issn.1006-1703.2018.11.018

PDF(3094 KB)

Labeled Immunoassays and Clinical Medicine ›› 2018, Vol. 25 ›› Issue (11) : 1650-1653. DOI: 10.11748/bjmy.issn.1006-1703.2018.11.018

The Comparison of Clinical Efficacy, Fusion Gene,Serum Markers and Prognosis of Crizotinib and Non-crizotinib treatment for EML4-ALK Positive Patients with Non Small Cell Lung Cancer

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2018, 25(11): 1650-1653 https://doi.org/10.11748/bjmy.issn.1006-1703.2018.11.018

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(3094 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Revised	Published
2018-07-26	2018-09-06	2018-11-20
Issue Date
2019-02-06

Please choose a citation manager

Content to export

HeighLight

Abstract

Key words

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

References

{{custom_fnGroup.title_en}}

Footnotes

{{custom_ack.title_en}}

Funding

RIGHTS & PERMISSIONS